Public health dispatch: update: cutaneous anthrax in a laboratory worker - Texas, 2002.
Page-EH; Martinez-KF; Seitz-TA; Bernard-BP; Tepper-AL; Weyant-RS; Quinn-CP; Rosenstein-NE; Perkins-BA; Popovic-T; Holmes-HT; Shepard-CW
MMWR 2002 Jun; 51(22):482
On April 5, 2002, CDC reported a case of suspected cutaneous anthrax in a worker at laboratory A who had been processing environmental samples for Bacillus anthracis in support of CDC investigations of the 2001 bioterrorist attacks in the United States (1). Since the initial report, the worker had serial serology performed at the CDC laboratory. A greater than fourfold rise from baseline in the concentration of immunoglobulin G to protective antigen was demonstrated. The peak antibody level was observed 7-8 weeks after the onset of symptoms, and the time course and levels of detectable antibodies were consistent with those seen in other cases of cutaneous anthrax. On the basis of case definitions developed during the recent investigation, these additional findings confirm this as a case of cutaneous anthrax (2). This case brings the number of anthrax cases identified in the United States since October 3, 2001, to 23, including 11 inhalation and 12 cutaneous (eight confirmed and four suspected). This is the first laboratory-acquired case of anthrax associated with the recent investigation.
Bacterial-disease; Bacterial-infections; Biological-weapons; Laboratories; Laboratory-testing; Laboratory-workers; Serology; Immunoglobulins; Antibody-response; Antigens; Employee-exposure; Epidemiology; Sampling; Region-6; Occupational-exposure
Morbidity and Mortality Weekly Report